50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)

Immuneering - IMRX Stock Forecast, Price & News

$10.59
+0.34 (+3.32%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.15
$10.90
50-Day Range
$5.58
$12.85
52-Week Range
$3.74
$33.25
Volume
27,281 shs
Average Volume
112,947 shs
Market Capitalization
$279.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.83

Immuneering MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
153.4% Upside
$26.83 Price Target
Short Interest
Bearish
3.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.99) to ($2.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

948th out of 1,069 stocks

Pharmaceutical Preparations Industry

463rd out of 533 stocks

IMRX stock logo

About Immuneering (NASDAQ:IMRX) Stock

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Receive IMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.

IMRX Stock News Headlines

Immuneering Flat on Latest IND
Immuneering Corporation (IMRX)
Immuneering GAAP EPS of -$0.42, revenue of $0.19M
See More Headlines
Receive IMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.

IMRX Company Calendar

Last Earnings
8/10/2022
Today
9/26/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMRX
Fax
N/A
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.83
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+153.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-33,540,000.00
Net Margins
-4,604.32%
Pretax Margin
-4,636.63%

Debt

Sales & Book Value

Annual Sales
$2.08 million
Book Value
$6.01 per share

Miscellaneous

Free Float
20,084,000
Market Cap
$279.49 million
Optionable
Not Optionable
Beta
1.11

Key Executives

  • Dr. Benjamin J. Zeskind M.B.A. (Age 39)
    MBA, Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $839.77k
  • Dr. Brett M. Hall Ph.D. (Age 54)
    Chief Scientific Officer
    Comp: $819.69k
  • Ms. Mallory Morales CPA (Age 39)
    VP of Fin., Principal Financial & Accounting Officer and Treasurer
  • Ms. Paula George CPA
    Sr. Mang. of Accounting & Operations
  • Mr. Michael D. Bookman J.D. (Age 34)
    Gen. Counsel & Sec.
  • Dr. Scott Barrett M.D. (Age 59)
    Chief Medical Officer
  • Dr. Mohamedi Kagalwala M.B.A.
    Ph.D., Head of Neuroscience Devel.
  • Dr. Peter King Ph.D.
    Head of Discovery & VP
  • Dr. Rajaraman Krishnan Ph.D.
    Head of Neuroscience Discovery
  • Dr. Andrew Lysaght Ph.D.
    VP & Head of Bioinformatics













IMRX Stock - Frequently Asked Questions

Should I buy or sell Immuneering stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMRX shares.
View IMRX analyst ratings
or view top-rated stocks.

What is Immuneering's stock price forecast for 2022?

5 analysts have issued 12-month price targets for Immuneering's shares. Their IMRX share price forecasts range from $12.00 to $41.00. On average, they predict the company's share price to reach $26.83 in the next twelve months. This suggests a possible upside of 153.4% from the stock's current price.
View analysts price targets for IMRX
or view top-rated stocks among Wall Street analysts.

How have IMRX shares performed in 2022?

Immuneering's stock was trading at $16.17 at the beginning of the year. Since then, IMRX stock has decreased by 34.5% and is now trading at $10.59.
View the best growth stocks for 2022 here
.

When is Immuneering's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our IMRX earnings forecast
.

How were Immuneering's earnings last quarter?

Immuneering Co. (NASDAQ:IMRX) posted its quarterly earnings results on Wednesday, August, 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.08. The business had revenue of $0.09 million for the quarter, compared to analysts' expectations of $0.27 million. Immuneering had a negative trailing twelve-month return on equity of 29.56% and a negative net margin of 4,604.32%.

When did Immuneering IPO?

(IMRX) raised $105 million in an initial public offering on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities served as the underwriters for the IPO.

What is Immuneering's stock symbol?

Immuneering trades on the NASDAQ under the ticker symbol "IMRX."

Who are Immuneering's major shareholders?

Immuneering's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (15.70%), Citadel Advisors LLC (8.34%), FMR LLC (0.85%), TD Asset Management Inc. (0.56%), Millennium Management LLC (0.49%) and Renaissance Technologies LLC (0.10%). Insiders that own company stock include Ann E Berman, Benjamin J Zeskind, Biren Amin, Brett Matthew Hall, Laurie Keating, Michael Bookman and Scott Barrett.
View institutional ownership trends
.

How do I buy shares of Immuneering?

Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immuneering's stock price today?

One share of IMRX stock can currently be purchased for approximately $10.59.

How much money does Immuneering make?

Immuneering (NASDAQ:IMRX) has a market capitalization of $279.49 million and generates $2.08 million in revenue each year. The company earns $-33,540,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis.

How can I contact Immuneering?

The official website for the company is www.immuneering.com. The company can be reached via phone at 617-500-8080 or via email at afields@rxir.com.

This page (NASDAQ:IMRX) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.